e-therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for e-therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	37.0%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?

Jan 10

Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?

Dec 06

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as e-therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

AIM:ETX - Analysts future estimates and past financials data (GBP Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
7/31/2023	0	-10	-10	-10	N/A
4/30/2023	0	-9	-9	-9	N/A
1/31/2023	0	-8	-8	-8	N/A
10/31/2022	0	-9	-9	-9	N/A
7/31/2022	0	-9	-10	-9	N/A
4/30/2022	0	-9	-9	-9	N/A
1/31/2022	0	-8	-8	-8	N/A
10/31/2021	1	-6	-6	-6	N/A
7/31/2021	1	-4	-5	-5	N/A
4/30/2021	1	-4	-4	-4	N/A
1/31/2021	0	-4	-3	-3	N/A
10/31/2020	0	-4	-3	-3	N/A
7/31/2020	0	-3	-3	-3	N/A
4/30/2020	0	-3	-3	-3	N/A
1/31/2020	0	-2	-2	-2	N/A
10/31/2019	0	-3	-2	-2	N/A
7/31/2019	0	-3	-2	-2	N/A
4/30/2019	0	-4	-3	-3	N/A
1/31/2019	0	-4	-4	-4	N/A
10/31/2018	0	-4	-4	-4	N/A
7/31/2018	N/A	-5	-5	-5	N/A
4/30/2018	N/A	-5	-5	-5	N/A
1/31/2018	N/A	-5	-4	-4	N/A
10/31/2017	N/A	-7	-6	-6	N/A
7/31/2017	N/A	-8	-7	-7	N/A
4/30/2017	N/A	-11	N/A	-8	N/A
1/31/2017	N/A	-13	N/A	-9	N/A
10/31/2016	N/A	-13	N/A	-9	N/A
7/31/2016	N/A	-12	N/A	-9	N/A
4/30/2016	N/A	-11	N/A	-9	N/A
1/31/2016	N/A	-9	N/A	-9	N/A
10/31/2015	N/A	-8	N/A	-8	N/A
7/31/2015	N/A	-8	N/A	-7	N/A
4/30/2015	N/A	-8	N/A	-8	N/A
1/31/2015	N/A	-8	N/A	-10	N/A
10/31/2014	N/A	-7	N/A	-9	N/A
7/31/2014	N/A	-7	N/A	-9	N/A
4/30/2014	N/A	-6	N/A	-7	N/A
1/31/2014	N/A	-5	N/A	-6	N/A
10/31/2013	N/A	-5	N/A	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ETX's forecast earnings growth is above the savings rate (1.8%).

Earnings vs Market: Insufficient data to determine if ETX's earnings are forecast to grow faster than the UK market

High Growth Earnings: Insufficient data to determine if ETX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ETX's revenue is forecast to grow faster than the UK market.

High Growth Revenue: Insufficient data to determine if ETX's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ETX's Return on Equity is forecast to be high in 3 years time

e-therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

e-therapeutics plc Considers Switching Its Listing to New York

e-therapeutics plc, Annual General Meeting, Apr 29, 2024

New minor risk - Market cap size

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

e-therapeutics Ordinary Shares to Cease to Trade on the OTCQX Best Market in the United States

New minor risk - Share price stability

e-therapeutics plc to Report First Half, 2024 Results on Oct 26, 2023

E-Therapeutics plc Announces Senior Management Update

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

e-therapeutics plc, Annual General Meeting, Jul 18, 2023

Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.017 loss in FY 2022)

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

Less than half of directors are independent

First half 2023 earnings released: UK£0.007 loss per share (vs UK£0.005 loss in 1H 2022)

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

e-therapeutics plc, Annual General Meeting, Jul 19, 2022

Full year 2022 earnings released: UK£0.016 loss per share (vs UK£0.01 loss in FY 2021)

Less than half of directors are independent

First half 2022 earnings released: UK£0.005 loss per share (vs UK£0.006 loss in 1H 2021)

CEO & Director recently bought UK£100k worth of stock

We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn

Full year 2021 earnings released: UK£0.01 loss per share (vs UK£0.009 loss in FY 2020)

e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £22.5 million.

Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?

e-Therapeutics plc Announces Board Changes

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

New 90-day high: UK£0.22

e-Therapeutics plc Announces Addition of its RNAi Platform as a Therapeutic Drug Modality

Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?

New 90-day high: UK£0.21

e-therapeutics plc Announces Results of Experimental Testing on the Compounds for the Treatment of Covid-19 Identified Using Its Proprietary Network-Driven Drug Discovery (Ndd) Platform

Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?

First half earnings released

e-therapeutics plc Announces Appointment of Ali Mortazavi as CEO

e-therapeutics plc to Report First Half, 2020 Results on Oct 12, 2020

e-therapeutics plc Announces Executive Changes

e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £0.75 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies